Teclistamab: Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome : 2 case reports.

Two case reports describe patients with relapsed/refractory multiple myeloma who developed cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) after receiving outpatient teclistamab step-up dosing. The first patient experienced grade 1 CRS and grade 1 ICANS, while the second patient had grade 2 CRS. Both patients were admitted for observation and management, and were treated with tocilizumab and dexamethasone. After treatment, both patients experienced prompt resolution of CRS/ICANS and were able to complete the step-up dosing without recurrence of the toxicities. [Extracted from the article]